Danger with Hydroxychloroquine Nonadherence in SLE
A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.
News
Hold the Methotrexate for One Week
In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with the "flu" vaccine.
SLE and Pregnancy Outcomes
Obstetric complications and poor pregnancy outcomes are not uncommon in women with SLE, especially with active disease. A large Spanish cohort trials shows that term pregnancy is more likely before the diagnosis of SLE and that poorer pregnancy outcomes were associated with antibody positivity to anticardiolipin IgG and anti-beta-2- glycoprotein IgG/IgM, but not lupus anticoagulant.
EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis
The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of PsA.
Anti-Drug Antibodies with Biologics (7.14.2023)
Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!
Filgotinib Effects on Semen and Sex Hormones
The oral Janus kinase 1 inhibitor filgotinib is available worldwide, but not in the USA, where the FDA held up its approval for use in RA due to unfinished studies of filgotinib's effects on sperm cells. The results of 2 phase two studies (MANTA and MANTA-RAy) confirm that filgotinib has no measurable impact on semen parameters or sex hormones in men with active IBD or inflammatory rheumatic diseases.
Antidrug Antibodies Impair Response to Biologic Drugs
Monitoring for antidrug antibodies with biologic has not been routine in rheumatology but a new study suggests that antidrug antibodies correlate with nonresponse to bDMARDs in rheumatoid arthritis (RA) patients.
Pegloticase Plus Methotrexate in Refractory Gout - MIRROR Study 12 mos. Results
The 12-month safety and efficacy of pegloticase + methotrexate (MTX) in the MIRROR trial shows continued efficacy and tophi resolution after 12 months of therapy.
Biologics Keep Early RA in Check for at Least One Year
MedPage Today
Treatment with at least some biologic drugs significantly reduced 1-year progression of early rheumatoid arthritis (RA) relative to classical small-molecule agents, researchers reported.
RA Biologics Lower COVID-19 Deaths, but Not Recovery Time
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
Baricitinib Effective in JIA Subsets
A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.
GCA and the Risk of Cerebrovascular Ischemic Events
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital.
